CoChat

Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis

Open access

The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.

Abstract

Background: BRAF mutations are found in 10% of colon cancers (CCs) and are associated with poor prognosis in metastatic disease. BRAF V600E predicts sensitivity to cetuximab + encorafenib in the metastatic setting. With new trials testing encorafenib-containing regimens for early-stage CC, we sought to characterize the clinical outcomes of early-stage BRAF V600E CC. Methods: We performed a systematic review and meta-analysis. Key inclusion criteria were a diagnosis of stage 2/3 BRAF V600E CC. Co-primary endpoints were overall survival (OS) and recurrence/disease-free survival (DFS). Meta-analysis was performed with a random-effects model incorporating sample size, hazard ratio (HR), and 95% confidence intervals (CIs). Results: A total of 206 studies underwent full-text review. Of these, six randomized controlled trials were included, comprising 6836 and 843 patients with wild-type (WT) and BRAF V600E, respectively. BRAF V600E was associated with inferior OS (HR 1.49, CI 1.21–1.75) and DFS (HR 1.17, CI 1.03–1.33). This finding remains in patients with microsatellite instability—low/stable or proficient mismatch repair (OS: HR 1.66, CI 1.36–2.02, DFS: HR 1.45, CI 1.22–1.72). Conclusions: BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/curroncol32110624

Cites

50 of 52 references verified0 citation errors · 2 not checkable

Statistics

Figures

Figure 1 PRISMA diagram demonstrating search and inclusion of studies for meta-analysis.
Figure 1 PRISMA diagram demonstrating search and inclusion of studies for meta-analysis.CC-BY · From the PDF
Figure 3 Quality assessment and risk-of-bias analysis. Pooled hazard ratios (HRs) of randomized controlled trials and retrospective studies comparing BRAF V600E to BRAF wild-type (WT) early-stage
Figure 3 Quality assessment and risk-of-bias analysis. Pooled hazard ratios (HRs) of randomized controlled trials and retrospective studies comparing BRAF V600E to BRAF wild-type (WT) early-stageCC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 4

Metadata

Authors
Dankner, M., Dubé, L.-R., Sorin, M., Stein, A. J. B., Nowakowski, A., Park, C. L., Magrill, J., Lazaratos, A.-M., Romero, J. M., Batist, G., Kavan, P., Rose, A. A. N., & Ma, K.
Affiliations
  • Jewish General Hospital (CA)
  • McGill University (CA)
  • Institut du cancer Rosalind & Morris Goodman (CA)
Corresponding author
Ma, Kim
Venue
Current Oncology
Publisher
MDPI AG
Published
2025-11-06
Volume
32
Issue
11
Pages
624
ISSN
  • 1198-0052 (ISSN-L)
  • 1718-7729
OpenAlex
W4415991529
Cited by
3
References
50
Citations by year
2026: 3
FWCI
0.35
Type
journal article
Language
en
Open access
Locations
  • Current Oncology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Pfizer pharmaceuticals
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
BRAF V600E mutation, early colon cancer, prognostic value, overall survival, disease-free survival, microsatellite instability, DNA mismatch repair, encorafenib, cetuximab, stage II and III colon cancer
MeSH terms
Colonic Neoplasms, Humans, Mutation, Neoplasm Staging, Prognosis, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.3390/curroncol32110624
The paper
Dankner, M., Dubé, L.-R., Sorin, M., Stein, A. J. B., Nowakowski, A., Park, C. L., Magrill, J., Lazaratos, A.-M., Romero, J. M., Batist, G., Kavan, P., Rose, A. A. N., & Ma, K. (2025). Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis. Current Oncology. https://doi.org/10.3390/curroncol32110624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.